Literature DB >> 9515574

Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.

A Kruczynski1, J M Barret, C Etiévant, F Colpaert, J Fahy, B T Hill.   

Abstract

This study aimed to define the mechanism of action of vinflunine, a novel Vinca alkaloid synthesised from vinorelbine using superacidic chemistry and characterised by superior in vivo activity to vinorelbine in preclinical tumour models. In vitro vinflunine cytotoxicity proved dependent on concentration and exposure duration, with IC50 values (72-hr exposures) generally ranging from 60-300 nM. Vinflunine induced G2 + M arrest, associated with mitotic accumulation and a concentration-dependent reduction of the microtubular network of interphase cells, accompanied by paracrystal formation. These effects, while comparable to those of vincristine, vinblastine or vinorelbine, were achieved with 3- to 17-fold higher vinflunine concentrations. However, vinflunine and the other Vincas all inhibited microtubule assembly at micromolar concentrations. Vinflunine, like vinblastine, vincristine and vinorelbine, appeared to interact at the Vinca binding domain, as judged by proteolytic cleavage patterns, and induced tubulin structural changes favouring an inhibition of GTP hydrolysis. However, vinflunine did not prevent [3H]vincristine binding to unassembled tubulin at concentrations < or = 100 microM, and only weakly inhibited binding of [3H]vinblastine or [3H]vinorelbine. Indeed, specific binding of [3H]vinflunine to tubulin was undetectable by centrifugal gel filtration. Thus, the comparative capacities of these Vincas to bind to or to interfere with their binding to tubulin could be classified as: vincristine > vinblastine > vinorelbine > vinflunine. By monitoring alkylation of sulfhydryl groups, differential effects on tubulin conformation were identified with vinflunine and vinorelbine acting similarly, yet distinctively from vinblastine and vincristine. Overall, vinflunine appears to function as a definite inhibitor of tubulin assembly, while exhibiting quantitatively different tubulin binding properties to the classic Vinca alkaloids.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9515574     DOI: 10.1016/s0006-2952(97)00505-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  27 in total

Review 1.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

Review 2.  Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.

Authors:  Holger Gerullis; Friedhelm Wawroschek; Claus-Henning Köhne; Thorsten Holger Ecke
Journal:  Ther Adv Urol       Date:  2016-11-21

Review 3.  Plant-derived natural product research aimed at new drug discovery.

Authors:  Hideji Itokawa; Susan L Morris-Natschke; Toshiyuki Akiyama; Kuo-Hsiung Lee
Journal:  J Nat Med       Date:  2008-04-22       Impact factor: 2.343

4.  Pharmacokinetics, tissue distribution and excretion of vinflunine.

Authors:  Xiao-Ping Zhao; Xiao-Quan Liu; Yong-Sheng Wang; Huan Wang; Guang-Ji Wang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

Review 5.  Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).

Authors:  Jorge García; Lucia Santomé; Urbano Anido; Ovidio Fernández-Calvo; Javier Afonso-Afonso; Martín Lázaro; Ana Medina; Sergio Vázquez Estévez
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

Review 6.  Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.

Authors:  Monique P Curran; Greg L Plosker
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

7.  Mitotic slippage in non-cancer cells induced by a microtubule disruptor, disorazole C1.

Authors:  Fengfeng L Xu; Youssef Rbaibi; Kirill Kiselyov; John S Lazo; Peter Wipf; William S Saunders
Journal:  BMC Chem Biol       Date:  2010-02-11

8.  Murine leukemia P388 vinorelbine-resistant cell lines are sensitive to vinflunine.

Authors:  Ashish Aggarwal; Anna Kruczynski; Anthony Frankfurter; John J Correia; Sharon Lobert
Journal:  Invest New Drugs       Date:  2007-12-11       Impact factor: 3.850

9.  Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development.

Authors:  A Kruczynski; C Etiévant; D Perrin; N Chansard; A Duflos; B T Hill
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

10.  Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folate-conjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM).

Authors:  Yuangang Zu; Yu Zhang; Xiuhua Zhao; Qi Zhang; Yang Liu; Ru Jiang
Journal:  Int J Nanomedicine       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.